Buscar

Estamos realizando la búsqueda. Por favor, espere...

 Detalle_Publicacion

Effectiveness and safety of inhaled antibiotics in patients with chronic obstructive pulmonary disease. A multicentre observational study

Abstract: Background We aimed to describe the effectiveness and safety of inhaled antibiotics in chronic obstructive pulmonary disease (COPD) patients, as well as the patient profile in which they are usually prescribed and the patient groups that can most benefit from this treatment. Methods Multicentre retrospective observational cohort study in COPD patients who had received ?1 dose of inhaled antibiotics in the last 5 years. Clinical data from the two years prior to and subsequent to the start of the treatment were compared. Primary outcome: COPD exacerbations. Secondary outcomes: side effects, symptomatology (sputum purulence, dyspnoea), microbiological profile and pathogen eradication. Results Of 693 COPD patients analyzed (aged 74.1; 86.3% men; mean FEV1 = 43.7%), 71.7% had bronchiectasis and 46.6% presented chronic bronchial infection (CBI) by Pseudomonas aeruginosa (PA). After 1 year of treatment with inhaled antibiotics, there was a significant decrease in the number of exacerbations (?33.3%; P < .001), hospital admissions (?33.3%; P < .001) and hospitalization days (?26.2%; P = .003). We found no difference in effectiveness between patients with or without associated bronchiectasis. Positive patient outcomes were more pronounced in PA-eradicated patients. We found a significant reduction in daily expectoration (?33.1%; P = .024), mucopurulent/purulent sputum (?53.9%; P < .001), isolation of any potentially pathogenic microorganisms (PPM) (?16.7%; P < .001), CBI by any PPM (?37.4%; P < .001) and CBI by PA (?49.8%; P < .001). CBI by any PPM and ?three previous exacerbations were associated with a better treatment response. 25.4% of patients presented non-severe side-effects, the most frequent of these being bronchospasm (10.5%), dyspnoea (8.8%) and cough (1.7%). Conclusions In COPD patients with multiple exacerbations and/or CBI by any PPM (especially PA), inhaled antibiotics appear to be an effective and safe treatment, regardless of the presence of bronchiectasis.

Otras publicaciones de la misma revista o congreso con autores/as de la Universidad de Cantabria

 Fuente: Archivos de Bronconeumología, 2022, 58, 11-21

Editorial: Elsevier Doyma

 Año de publicación: 2022

Nº de páginas: 11

Tipo de publicación: Artículo de Revista

 DOI: 10.1016/j.arbres.2021.03.009

ISSN: 0300-2896,1579-2129

Url de la publicación: https://doi.org/10.1016/j.arbres.2021.03.009

Autores/as

ROSA CARRILLO, DAVID DE LA

MARTÍNEZ-GARCÍA, MIGUEL ÁNGEL

BARREIRO, ESTHER

TABERNERO HUGUET, EVA

COSTA SOLA, ROSER

GARCÍA-CLEMENTE, MARTA MARÍA

CELORRIO JIMÉNEZ, NURIA

RODRÍGUEZ PONS, LAURA

CALERO ACUÑA, CARMEN

RODRÍGUEZ HERMOSA, JUAN LUIS

GOLPE, RAFAEL

DACAL QUINTAS, RAQUEL

SÁNCHEZ-CUÉLLAR, SILVIA

TORRES ARROYO, IRENE

BLANCO APARICIO, MARINA

ALMADANA PACHECO, VIRGINIA

MIRAVITLLES, MARCA